Albany Molecular Research, Inc. (AMRI)

[surf1944]

8:06AM Albany Molecular beats on top and bottom line; issues upside guidance (AMRI) 5.66 : Reports Q4 (Dec) earnings of $0.17 per share, $0.08 better than the Capital IQ single analyst estimate of $0.09; revenues rose 44.2% year/year to $67.2 mln vs the $56.5 mln single analyst est.

Total contract revenue for the fourth quarter of 2012 was $59.1 million, an increase of 50% compared to total contract revenue of $39.4 million reported in the fourth quarter of 2011. Contract margin improved to 18% from (2%) in the prior-year period.
Co issues upside guidance for FY13, sees EPS of $0.34-0.52 vs. $0.24 Capital IQ single analyst est. Sees contract revenue growth between 8% and 12%; continued improvement in contract margin to between 14% and 16%.
"We are pleased to report fourth quarter and full year results for 2012, which reflect operating improvements largely driven by the record performance in our Large Scale Manufacturing business. In addition, a number of actions taken in prior periods are demonstrating a positive impact on our bottom line."